image

Degenerative Disc Disease Treatment Market Report Scope & Overview:

The Degenerative Disc Disease Treatment Market size was valued at USD 30.32 billion in 2023 and is estimated to reach at USD 55.75 billion in 2031 and grow at a compound annual growth rate approx. CAGR of 7.91% predicted for the forecast period of 2024-2031

According to the Centres for Disease Control and Prevention (CDC), degenerative bone disease will affect those 64 and older more often in 2021. By 2040, approximately 77 million (28%) of American adults aged 18 and older are expected to have arthritis, according to the CDC. This suggests that the patient population for degenerative bone disease will be quite large. The demand for the product will rise due to the disease's high prevalence.

Degenerative Disc Disease Treatment Market Revenue Analysis

The intervertebral discs in the spine are impacted by degenerative disc disease (DDD), which over time causes them to deteriorate and lose their flexibility. Treatment for degenerative disc disease (DDD) comprises symptom management in stages. Physical therapy, painkillers, and lifestyle changes are all frequent conservation measures. Epidural steroid injections may be used in specific circumstances to alleviate inflammation. For severe instances, surgical intervention such as a discectomy, spinal fusion, or artificial disc replacement may be considered. The intensity of the symptoms, disc degeneration, and a person's health all influence the therapy option.

MARKET DYNAMICS

DRIVERS

  • Degenerative disc disease is becoming more common.

  • Advancements in Technology for Minimally Invasive Procedures, An Increase in the Demand for Non-Surgical Options.

A significant factor in the market's growth is the increased prevalence of DDD, which is mostly caused by an ageing population and sedentary lifestyles. The need for efficient treatment alternatives grows as the prevalence of DDD rises.

The emergence of minimally invasive techniques like disc nucleoplasty and percutaneous disc decompression is a result of advancements in medical technology. These methods promote market expansion by providing less intrusive treatment alternatives with quicker recoveries.

RESTRAIN

  • Insufficient long-term effectiveness data and expensive surgical interventions.

Although there are many therapeutic options, long-term evidence on their effectiveness and results are still needed. The low number of long-term studies available may limit the use of particular therapy modalities and affect patient and doctor decision-making.

 The cost of surgical procedures for DDD, such spinal fusion and artificial disc replacement, can be high. These treatments' high cost may make them less accessible, especially in areas with little healthcare resources and tight budgets.

OPPORTUNITY

  • New Methods in Regenerative Medicine.

  • Growing Attention on Patient-Centered Care.

Tissue engineering and cell-based treatments in regenerative medicine have the potential to cure DDD. Opportunities for novel and regenerative therapy approaches are presented by ongoing studies and clinical trials examining the use of stem cells, growth factors, and biomaterials. In order to treat DDD, there is an increasing emphasis on patient-centered therapy that emphasises individualised treatment plans. therapy results and patient satisfaction may be improved by adjusting therapy options in accordance with personal traits, preferences, and illness severity.

CHALLENGES

  • Potential Complications and Adverse Events.

A multifactorial disorder with different levels of severity and symptomatology is degenerative disc disease. The complexity of the illness makes it difficult to properly diagnose and treat patients since the best course of action may vary depending on the condition. Despite sometimes being successful, surgical procedures have risks of complications and unfavorable outcomes. The difficulty is in reducing these risks and providing the best possible patient outcomes while taking into account any potential trade-offs related to surgical treatments.

IMPACT OF RUSSIAN UKRAINE WAR

We constantly study the report and update news in light of the ongoing political and economic unpredictability caused by the Russia-Ukraine Conflict. Around the world, negative effects are anticipated, particularly in Eastern Europe, the European Union, Eastern & Central Asia, and the United States. This claim has significantly disrupted trade dynamics and had a negative impact on people's lives and means of subsistence. It is anticipated that the continued conflict and unpredictability in Eastern Europe would negatively affect Ukraine and have severe, long-lasting impacts on Russia. In light of the most recent information on the war and the world's responses, the research explores the implications for demand-supply balances, pressure on pricing variations, influence on import/export and trade, and short-term suggestions to the global degenerative disc disease market.

IMPACT OF ONGOING RECESSION

Over the past two years, there has been a general price increase as a result of the rising inflation in industrialised economies throughout the world. It is anticipated that the aggregate buying power would considerably affect emerging economies and is thought to be beneficial in many ways. The paper reveals how high inflation affects the long-term health of the global economy and offers information on the fiscal measures that may be taken to lessen its short-term effects on demand/supply, cash flow, and currency exchange. About 42% of the market's overall growth is expected to originate from the region. Given the influence of cost-push and demand-pull inflation, the Global Degenerative Disc Disease Market research predicts substantial inflation.

MARKET SEGMENTATION

KEY MARKET SEGMENTS

By Product Type

  • Drugs

    • Acetaminophen

    • NSAIDs

    • Oral Steroids

    • Muscle Relaxants

  • Devices

    • Cervical Spine

    • Lumbar Spine

    • Thoracic Spine

    • Spinal Fusion

By End users

  • Hospitals

  • Ambulatory Surgical centers

  • Orthopedic center

  • Other

Degenerative Disc Disease Treatment Market Segmentation Analysis

REGIONAL COVERAGE:

North America

  • USA

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

Asia-Pacific

  • Japan

  • South Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of the Middle East & Africa

Latin America

  • Brazil

  • Argentina

  • Rest of Latin American

REGIONAL ANALYSES

North America:

The market for treatments for degenerative disc disease in North America, with a market value of USD 9.6 billion, held the largest market share in 2021. During the projected period, a higher CAGR is anticipated for the area. The dominance is attributed to the region's rising desire for innovative cures. This is anticipated to drive the expansion of the market in the area, coupled with the growing number of mergers and acquisitions among the industry competitors for the therapy.

Asia-Pacific:

On the other hand, the Asia Pacific market is anticipated to experience the highest CAGR growth during the forecast period due to the region's rising diagnosis of the condition and rising prevalence of chronic low back pain among the population, both of which are driving up demand for the drugs used to treat the condition. Additionally, throughout the forecast period, the market expansion in the Asia Pacific region is anticipated to be fuelled by increasing efforts made by market participants to secure approvals for clinic trials in nations like Japan, South Korea, and others.

Key Players

The key players are DiscGenics Inc., Medtronic, Spine BioPharma Inc., Globus Medical, Johnson & Johnson Services, Inc., Zimmer Biomet, B. Braun SE, RTI Surgical, Cousin Biotech, ulrich medical USA, Fresenius Kabi AG, Abbott, Spine Wave, Inc., RIVANNA MEDICAL, ZAVATION, Orthofix US LLC., Spinal Simplicity, Nexus Spine, NuVasive, Inc., Aurora Spine, Inc., and others.

Medtronic-Company Financial Analysis

Company Landscape Analysis

RECENT DEVELOPMENT

DiscGenics Inc:

In January 2023, DiscGenics Inc. announced that the U.S. FDA had given its injectable Disc cell therapy (IDCT or rebonuputemcel), an injectable, allogenic progenitor cell therapy for the treatment of symptomatic lumbar degenerative disc diseases (DDD), the designation of regenerative medicine advanced therapy (RMAT). This advancement serves as a crucial confirmation of the company's innovative strategy to treat disc degeneration using a synthetic living progenitor cell population obtained from donated adult human intervertebral disc tissue.

Spine BioPharma Inc:

Pharma business got a USD 13 million series B round of investment in March 2022 for an injectable degenerative disc disease treatment. As a result of investment, the firm was able to create the first-class therapeutic SB-01 for the treatment of degenerative disc disease and increase income.

Degenerative Disc Disease Treatment Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 28.1 Bn
Market Size by 2030  US$ 51.24 Bn
CAGR   CAGR of 7.8 % From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product Type (Drugs, Devices)
• By End users (Hospitals, Ambulatory surgical centers, Orthopaedic centers)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles DiscGenics Inc., Medtronic, Spine BioPharma Inc., Globus Medical, Johnson & Johnson Services, Inc., Zimmer Biomet, B. Braun SE, RTI Surgical, Cousin Biotech, ulrich medical USA, Fresenius Kabi AG, Abbott, Spine Wave, Inc., RIVANNA MEDICAL, ZAVATION, Orthofix US LLC., Spinal Simplicity, Nexus Spine, NuVasive, Inc., Aurora Spine, Inc., and others
Key Drivers • Degenerative disc disease is becoming more common.
• Advancements in Technology for Minimally Invasive Procedures, An Increase in the Demand for Non-Surgical Options.
Market Opportunities • New Methods in Regenerative Medicine.
• Growing Attention on Patient-Centered Care.

 

Frequently Asked Questions

Ans: The CAGR Growth rate of Degenerative Disc Disease Treatment Market is approx. CAGR 7.8% for the forecast period of 2023-2030.

Ans: The projected market size of Degenerative Disc Disease Treatment Market at USD 28.1 billion in 2022 and is poised to reach at 51.24 billion in 2030.

Ans: The key players are DiscGenics Inc., Medtronic, Spine BioPharma Inc., Globus Medical, Johnson & Johnson Services, Inc., Zimmer Biomet, B. Braun SE, RTI Surgical, Cousin Biotech, ulrich medical USA, Fresenius Kabi AG, Abbott, Spine Wave, Inc., RIVANNA MEDICAL, ZAVATION, Orthofix US LLC., Spinal Simplicity, Nexus Spine, NuVasive, Inc., Aurora Spine, Inc., and others

Ans: By type, Drug segment can lead the market.

Ans: Due to the rising frequency of degenerative disc disease (DDD), as well as improvements in medical technology and a growing population, North America accounted for over 57% of the global market for degenerative disc disease treatments in 2022.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of the Ukraine- Russia War
4.3 Impact of Ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Degenerative Disc Disease Treatment Market, By Product Type
8.1     Drugs
8.2    Devices

9. Degenerative Disc Disease Treatment Market, By End-User
9.1    Hospitals
9.2    Ambulatory Surgical centers
9.3    Orthopedic center
9.4    Other

10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Degenerative Disc Disease Treatment Market, by country
10.2.2North America Degenerative Disc Disease Treatment Market by Product Type
10.2.3 North America Degenerative Disc Disease Treatment Market by End-User
10.2.4 USA
10.2.4.1 USA Degenerative Disc Disease Treatment Market by Product Type
10.2.4.2 USA Degenerative Disc Disease Treatment Market by End-User
10.2.7 Canada
10.2.7.1 Canada Degenerative Disc Disease Treatment Market by Product Type
10.2.7.2 Canada Degenerative Disc Disease Treatment Market by End-User
10.2.8 Mexico
10.2.8.1 Mexico Degenerative Disc Disease Treatment Market by Product Type
10.2.8.2 Mexico Degenerative Disc Disease Treatment Market by End-User
10.3 Europe
10.3.1 Europe Degenerative Disc Disease Treatment Market by country
10.3.3.2 Europe Degenerative Disc Disease Treatment Market by Product Type
10.3.3 Europe Degenerative Disc Disease Treatment Market by End-User
10.3.6 Germany
10.3.6.1 Germany Degenerative Disc Disease Treatment Market by Product Type
10.3.6.2 Germany Degenerative Disc Disease Treatment Market by End-User
10.3.7 UK
10.3.7.1 UK Degenerative Disc Disease Treatment Market by Product Type
10.3.7.2 UK Degenerative Disc Disease Treatment Market by End-User
10.3.8 France
10.3.8.1 France Degenerative Disc Disease Treatment Market by Product Type
10.3.8.2 France Degenerative Disc Disease Treatment Market by End-User
10.3.9 Italy
10.3.9.1 Italy Degenerative Disc Disease Treatment Market by Product Type
10.3.9.2 Italy Degenerative Disc Disease Treatment Market by End-User
10.3.10 Spain
10.3.10.1 Spain Degenerative Disc Disease Treatment Market by Product Type
10.3.10.2 Spain Degenerative Disc Disease Treatment Market by End-User
10.3.11 The Netherlands
10.3.11.1 Netherlands Degenerative Disc Disease Treatment Market by Product Type
10.3.11.2 Netherlands Degenerative Disc Disease Treatment Market by End-User
10.3.12 Rest of Europe
10.3.12.1 Rest of Europe Degenerative Disc Disease Treatment Market by Product Type
10.3.12.2 Rest of Europe Degenerative Disc Disease Treatment Market by End-User
10.4 Asia-Pacific
10.4.1 Asia Pacific Degenerative Disc Disease Treatment Market by country
10.4.2 Asia Pacific Degenerative Disc Disease Treatment Market by Product Type
10.4.3 Asia Pacific Degenerative Disc Disease Treatment Market by End-User
10.4.6 Japan
10.4.6.1 Japan Degenerative Disc Disease Treatment Market by Product Type
10.4.6.2 Japan Degenerative Disc Disease Treatment Market by End-User
10.4.7 South Korea
10.4.7.1 South Korea Degenerative Disc Disease Treatment Market by Product Type
10.4.7.2 South Korea Degenerative Disc Disease Treatment Market by End-User
10.4.8 China
10.4.8.1 China Degenerative Disc Disease Treatment Market by Product Type
10.4.8.2 China Degenerative Disc Disease Treatment Market by End-User
10.4.9 India
10.4.9.1 India Degenerative Disc Disease Treatment Market by Product Type
10.4.9.2 India Degenerative Disc Disease Treatment Market by End-User
10.4.10 Australia
10.4.10.1 Australia Degenerative Disc Disease Treatment Market by Product Type
10.4.10.2 Australia Degenerative Disc Disease Treatment Market by End-User
10.4.11 Rest of Asia-Pacific
10.4.11.1 APAC Degenerative Disc Disease Treatment Market by Product Type
10.4.11.2 APAC Degenerative Disc Disease Treatment Market by End-User
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Degenerative Disc Disease Treatment Market by country
10.5.2 The Middle East & Africa Degenerative Disc Disease Treatment Market by Product Type
10.5.3 The Middle East & Africa Degenerative Disc Disease Treatment Market by End-User
10.5.6 Israel
10.5.6.1 Israel Degenerative Disc Disease Treatment Market by Product Type
10.5.6.2 Israel Degenerative Disc Disease Treatment Market by End-User
10.5.7 UAE
10.5.7.1 UAE Degenerative Disc Disease Treatment Market by Product Type
10.5.7.2 UAE Degenerative Disc Disease Treatment Market by End-User
10.5.8 South Africa
10.5.8.1 South Africa Degenerative Disc Disease Treatment Market by Product Type
10.5.8.2 South Africa Degenerative Disc Disease Treatment Market by End-User
10.5.9 Rest of Middle East & Africa
10.5.9.1 Rest of Middle East & Asia Degenerative Disc Disease Treatment Market by Product Type
10.5.9.2 Rest of Middle East & Asia Degenerative Disc Disease Treatment Market by End-User
10.6 Latin America
10.6.1 Latin America Degenerative Disc Disease Treatment Market by country
10.6.2 Latin America Degenerative Disc Disease Treatment Market by Product Type
10.6.3 Latin America Degenerative Disc Disease Treatment Market by End-User
10.6.6 Brazil
10.6.6.1 Brazil Degenerative Disc Disease Treatment Market by Product Type
10.6.6.2 Brazil Africa Degenerative Disc Disease Treatment Market by End-User
10.6.7 Argentina
10.6.7.1 Argentina Degenerative Disc Disease Treatment Market by Product Type
10.6.7.2 Argentina Degenerative Disc Disease Treatment Market by End-User
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Degenerative Disc Disease Treatment Market by Product Type
10.6.8.2 Rest of Latin America Degenerative Disc Disease Treatment Market by End-User

11. Company profile
11.1 DiscGenics Inc.
11.1.1 Market Overview
11.1.2 Financials
11.1.3 Treatment/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Medtronic.
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Treatment/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 Spine BioPharma Inc.
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Treatment/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Globus Medical.
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Treatment/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Johnson & Johnson Services, Inc.
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Treatment/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Zimmer Biomet.
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Treatment/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 B. Braun SE.
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Treatment/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 RTI Surgical.
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Treatment/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Cousin Biotech.
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Treatment/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Aurora Spine, Inc.
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Treatment/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View

12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments

13. Use Case and Best Practices

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone